<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284243</url>
  </required_header>
  <id_info>
    <org_study_id>REC-14-013</org_study_id>
    <nct_id>NCT02284243</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recro Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lotus Clinical Research, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Recro Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the analgesic efficacy, on Post-Operative
      Day (POD) 1, of DEX-IN compared with placebo, using the summed pain intensity difference over
      the first 48 hours (SPID48) in subjects with acute moderate to severe pain following
      unilateral bunionectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summed Pain Intensity Difference Over the First 48 Hours (SPID48).</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SPID at Various Other Time Points</measure>
    <time_frame>Up to 48 Hours</time_frame>
    <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Perceptible and Meaningful Pain Relief</measure>
    <time_frame>6 hours</time_frame>
    <description>Kaplan-Meier analysis of time to perceptible and meaningful pain relief for 50th percentile of subjects. Time to perceptible pain relief and time to meaningful pain relief were measured using the double-stopwatch method. The first stopwatch was given to each subject with the instructions to stop the watch when they first perceive pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they are first experiencing meaningful pain relief (time to meaningful relief). A shorter time to pain relief is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Significant Pain Improvement Following the First Study Dose.</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication (Oral Opioids)</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of subjects requiring rescue medication (Oral opioids) within 48 hours after first study dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Rescue Medication Use</measure>
    <time_frame>48 hours</time_frame>
    <description>Kaplan Meier analysis of time to first use of rescue analgesia 50th percentile of subjects. Rescue analgesia (oral oxycodone) was available to subjects with inadequately controlled pain. All doses of rescue analgesia administered were recorded and the time from the first study dose to first rescue analgesia in each subject was evaluated. A longer time to first rescue is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Complete Protection From PONV</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Pain, Post-operative</condition>
  <arm_group>
    <arm_group_label>DEX-IN 50mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IN Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IN Placebo every 6 hours for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Dexmedetomidine</intervention_name>
    <arm_group_label>DEX-IN 50mcg</arm_group_label>
    <other_name>DEX-IN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Placebo</intervention_name>
    <arm_group_label>IN Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily provide written informed consent.

          -  Male or female between 18 and 70 years of age, inclusive.

          -  Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair

          -  Be American Society of Anesthesiology (ASA) physical class 1 or 2.

          -  Female subject are eligible only if all the following apply:

               -  Not pregnant;

               -  Not lactating;

               -  Not planning to become pregnant during the study;

               -  Be surgically sterile; or at least two year post menopausal; or have a monogamous
                  partner who is surgically sterile; or is practicing double-barrier contraception;
                  or practicing abstinence; or using an insertable, injectable, transdermal, or
                  combination oral contraceptive.

          -  Male subjects must be surgically sterile or commit to the use of a reliable method of
             birth control

          -  Have a body mass index â‰¤35 kg/m2

          -  Be able to understand the study procedures, comply with all study procedures, and
             agree to participate in the study program.

        Exclusion Criteria:

          -  Have a known allergy to dexmedetomidine or any excipient in DEX-IN/placebo or to any
             peri- or postoperative medications used in this study.

          -  Have a clinically significant abnormal clinical laboratory test value.

          -  Have history of or positive test results for HIV, or hepatitis B or C.

          -  Have a history or clinical manifestations of significant renal, hepatic,
             cardiovascular, metabolic, neurologic, psychiatric, or other condition that would
             preclude participation in the study.

          -  Have a history of migraine or frequent headaches, seizures, or are currently taking
             anticonvulsants.

          -  Have another painful physical condition that may confound the assessments of post
             operative pain.

          -  Have a history of syncope or other syncopal attacks.

          -  Have evidence of a clinically significant 12 lead ECG abnormality.

          -  Have a history of alcohol abuse (regularly drinks &gt; 4 units of alcohol per day; 8 oz.
             beer, 3 oz. wine, 1 oz. spirits) or prescription/illicit drug abuse..

          -  Have positive results on the urine drug screen or alcohol breath test indicative of
             illicit drug or alcohol abuse.

          -  Have a history or evidence of orthostatic hypotension.

          -  Have a resting heart rate of &lt;50 beats per minutes or systolic blood pressure
             &lt;100mmHg.

          -  Have been receiving or have received chronic opioid therapy defined as greater than 15
             morphine equivalents units per day for greater than 3 out of 7 days per week over a
             one-month period within 12 months.

          -  Use concurrent therapy that could interfere with the evaluation of efficacy or safety,
             such as any drugs which in the investigator's opinion may exert significant analgesic
             properties or act synergistically with DEX-IN.

          -  Unable to discontinue medications, that have not been at a stable dose for at least 14
             days prior to the scheduled bunionectomy procedure, within 5 half lives of the
             specific prior medication (or, if half life is not known, within 48 hours) before
             dosing.

          -  Have utilized any intranasal medications within the preceding 10 days.

          -  Have signs or a history of significant rhinitis or rhinorrhea (constant or chronic),
             nasal polyps, mucosal lesions of the nostril, postnasal drip of any etiology (constant
             or chronic), nasal ulcers, septal perforation or deviation, any nasal surgery,
             anosmia, nasal piercings, or frequent nosebleeds or other nasal pathology, that is
             sufficient to interfere with IN drug delivery.

          -  Have had an upper respiratory tract infection within 14 days of screening.

          -  Have utilized corticosteroids, either systemically, inhalational either intranasally
             or oral, or by intra-articular injection, within 14 days prior to the study.

          -  Have received any investigational product within 30 days before dosing with study
             medication.

          -  Have previously received DEX-IN in clinical trials, or had bunionectomy in the last 3
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Singla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Clinical Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trovare Clinical Research, Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <results_first_submitted>January 16, 2017</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2017</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bunion</keyword>
  <keyword>Bunionectomy</keyword>
  <keyword>Pain</keyword>
  <keyword>Analgesia</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>intranasal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DEX-IN 50mcg</title>
          <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
        </group>
        <group group_id="P2">
          <title>IN Placebo</title>
          <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set - All subjects receiving at least one study dose</population>
      <group_list>
        <group group_id="B1">
          <title>DEX-IN 50mcg</title>
          <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
        </group>
        <group group_id="B2">
          <title>IN Placebo</title>
          <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" spread="12.37"/>
                    <measurement group_id="B2" value="44.0" spread="13.08"/>
                    <measurement group_id="B3" value="44.0" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="4.31"/>
                    <measurement group_id="B2" value="27.4" spread="4.08"/>
                    <measurement group_id="B3" value="27.0" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline pain intensity score (NPRS)</title>
          <description>Pain intensity was recorded using a Numeric Rating Scale (Range 0-10) where 0 equates to no pain, and 10 equates to the worst pain imaginable.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4" spread="1.42"/>
                    <measurement group_id="B2" value="6.7" spread="1.90"/>
                    <measurement group_id="B3" value="6.5" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summed Pain Intensity Difference Over the First 48 Hours (SPID48).</title>
        <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.</description>
        <time_frame>48 hours</time_frame>
        <population>mITT population, including all randomized subjects who received at least one study dose</population>
        <group_list>
          <group group_id="O1">
            <title>DEX-IN 50mcg</title>
            <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>IN Placebo</title>
            <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Summed Pain Intensity Difference Over the First 48 Hours (SPID48).</title>
          <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.</description>
          <population>mITT population, including all randomized subjects who received at least one study dose</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2328.2" spread="5746.724"/>
                    <measurement group_id="O2" value="-548.90" spread="5819.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0180</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SPID at Various Other Time Points</title>
        <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.</description>
        <time_frame>Up to 48 Hours</time_frame>
        <population>mITT population, including all randomized subjects who received at least one study dose</population>
        <group_list>
          <group group_id="O1">
            <title>DEX-IN 50mcg</title>
            <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>IN Placebo</title>
            <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>SPID at Various Other Time Points</title>
          <description>Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline were calculated at each time point and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation.</description>
          <population>mITT population, including all randomized subjects who received at least one study dose</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPID 0-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-346.57" spread="579.0378"/>
                    <measurement group_id="O2" value="-120.46" spread="590.7313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 0-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-568.89" spread="1213.410"/>
                    <measurement group_id="O2" value="-151.93" spread="1263.656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1043.2" spread="2553.890"/>
                    <measurement group_id="O2" value="-239.07" spread="2717.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Applies to SPID 0-6, SPID 0-12, and SPID 0-24</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Perceptible and Meaningful Pain Relief</title>
        <description>Kaplan-Meier analysis of time to perceptible and meaningful pain relief for 50th percentile of subjects. Time to perceptible pain relief and time to meaningful pain relief were measured using the double-stopwatch method. The first stopwatch was given to each subject with the instructions to stop the watch when they first perceive pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they are first experiencing meaningful pain relief (time to meaningful relief). A shorter time to pain relief is better.</description>
        <time_frame>6 hours</time_frame>
        <population>mITT population, including all randomized subjects who received at least one study dose</population>
        <group_list>
          <group group_id="O1">
            <title>DEX-IN 50mcg</title>
            <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>IN Placebo</title>
            <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Perceptible and Meaningful Pain Relief</title>
          <description>Kaplan-Meier analysis of time to perceptible and meaningful pain relief for 50th percentile of subjects. Time to perceptible pain relief and time to meaningful pain relief were measured using the double-stopwatch method. The first stopwatch was given to each subject with the instructions to stop the watch when they first perceive pain relief to occur (time to perceptible relief). Once the first watch was stopped, the second stopwatch was given to the subject with the instructions to stop the watch when they are first experiencing meaningful pain relief (time to meaningful relief). A shorter time to pain relief is better.</description>
          <population>mITT population, including all randomized subjects who received at least one study dose</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to perceptible pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.39" lower_limit="15.50" upper_limit="25.68"/>
                    <measurement group_id="O2" value="33.0" lower_limit="18.18" upper_limit="85.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to meaningful pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.32" lower_limit="55.25" upper_limit="151.88"/>
                    <measurement group_id="O2" value="NA">Sufficient number of subjects did not achieve endpoint for analysis</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Applies to perceptible and meaningful pain relief</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Significant Pain Improvement Following the First Study Dose.</title>
        <time_frame>6 hours</time_frame>
        <population>mITT population, including all randomized subjects who received at least one study dose</population>
        <group_list>
          <group group_id="O1">
            <title>DEX-IN 50mcg</title>
            <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>IN Placebo</title>
            <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Significant Pain Improvement Following the First Study Dose.</title>
          <population>mITT population, including all randomized subjects who received at least one study dose</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>â‰¥30% reduction in pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥50% reduction in pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Applies to â‰¥30% and â‰¥50% reduction in pain</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Test for general association stratified by site</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication (Oral Opioids)</title>
        <description>Number of subjects requiring rescue medication (Oral opioids) within 48 hours after first study dose</description>
        <time_frame>48 hours</time_frame>
        <population>mITT population, including all randomized subjects who received at least one study dose</population>
        <group_list>
          <group group_id="O1">
            <title>DEX-IN 50mcg</title>
            <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>IN Placebo</title>
            <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication (Oral Opioids)</title>
          <description>Number of subjects requiring rescue medication (Oral opioids) within 48 hours after first study dose</description>
          <population>mITT population, including all randomized subjects who received at least one study dose</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Rescue Medication Use</title>
        <description>Kaplan Meier analysis of time to first use of rescue analgesia 50th percentile of subjects. Rescue analgesia (oral oxycodone) was available to subjects with inadequately controlled pain. All doses of rescue analgesia administered were recorded and the time from the first study dose to first rescue analgesia in each subject was evaluated. A longer time to first rescue is better.</description>
        <time_frame>48 hours</time_frame>
        <population>mITT population, including all randomized subjects who received at least one study dose</population>
        <group_list>
          <group group_id="O1">
            <title>DEX-IN 50mcg</title>
            <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>IN Placebo</title>
            <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Rescue Medication Use</title>
          <description>Kaplan Meier analysis of time to first use of rescue analgesia 50th percentile of subjects. Rescue analgesia (oral oxycodone) was available to subjects with inadequately controlled pain. All doses of rescue analgesia administered were recorded and the time from the first study dose to first rescue analgesia in each subject was evaluated. A longer time to first rescue is better.</description>
          <population>mITT population, including all randomized subjects who received at least one study dose</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" lower_limit="4.03" upper_limit="7.85"/>
                    <measurement group_id="O2" value="2.68" lower_limit="1.42" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Complete Protection From PONV</title>
        <time_frame>24 hours</time_frame>
        <population>mITT population, including all randomized subjects who received at least one study dose</population>
        <group_list>
          <group group_id="O1">
            <title>DEX-IN 50mcg</title>
            <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>IN Placebo</title>
            <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Complete Protection From PONV</title>
          <population>mITT population, including all randomized subjects who received at least one study dose</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7718</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs were collected through the Day 7 study visit. All SAEs were assessed through the Day 7 visit, but were reported through 30 days of the last study visit if the investigator was made aware of the event.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DEX-IN 50mcg</title>
          <description>DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
Intranasal Dexmedetomidine</description>
        </group>
        <group group_id="E2">
          <title>IN Placebo</title>
          <description>IN Placebo every 6 hours for 48 hours.
Intranasal Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="84"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision Site Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Decreased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="84"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nasal Discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nasal Dryness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nasal Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nasal Obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Upper-Airway Cough Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Randall Mack</name_or_title>
      <organization>Recro Pharma</organization>
      <phone>484-395-2470 ext 2406</phone>
      <email>rmack@recropharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

